What is Anika Therapeutics's stock-based comp?

Anika Therapeutics (ANIK) reported stock-based comp of $1.83M in Q2 2026.

How has Anika Therapeutics's stock-based comp changed year-over-year?

Anika Therapeutics's stock-based comp decreased by 28.1% year-over-year, from $2.55M to $1.83M.

What is the long-term trend for Anika Therapeutics's stock-based comp?

Over 4 years (2021 to 2025), Anika Therapeutics's stock-based comp has grown at a -2.3% compound annual growth rate (CAGR), from $11.09M to $10.08M.

Anika Therapeutics ANIK Stock-Based Comp

Stock-Based Comp at other companies

Globus MedicalGMED

——

AVN

AVNSAVNS

——

Envista Holdings CorporationNVST

——

Other financials

Income statement

See full

Revenue$32.6M+15.6%

Net income$3.3M+183%

EPS (diluted)$0.24—

Balance sheet

See full

Cash & equivalents$38.4M-27.8%

Total debt$25.7M+1.2%

Total equity$137.3M-7.0%

Total assets$183.5M-2.2%

Cash flow

See full

Operating cash flow-$684.0K-262%

CapEx$1.4M-1.2%

Free cash flow-$2.1M-28.8%

Valuation

See full

Market cap$199.85M+23.0%

P/S1.7×-0.1×

Profitability

See full

Net margin-3.4%-1.6pp

FCF margin0.5%—

Returns & leverage

See full

Return on equity-2.9%-1.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.7×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Anika Therapeutics’s 8-K, filed July 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Anika Therapeutics's stock-based comp?: Anika Therapeutics (ANIK) reported stock-based comp of $1.83M in Q2 2026.
How has Anika Therapeutics's stock-based comp changed year-over-year?: Anika Therapeutics's stock-based comp decreased by 28.1% year-over-year, from $2.55M to $1.83M.
What is the long-term trend for Anika Therapeutics's stock-based comp?: Over 4 years (2021 to 2025), Anika Therapeutics's stock-based comp has grown at a -2.3% compound annual growth rate (CAGR), from $11.09M to $10.08M.